 |
市场调查报告书
商品编码
1890982
药物再利用市场按方法、药物类型、治疗领域、给药途径、最终用户和地区划分Drug Repurposing Market, By Approach, By Drug Type, By Therapeutic Area, By Route of Administration, By End User, By Geography |
||||||
预计到 2025 年，药物再利用市场价值将达到 351.4 亿美元，到 2032 年将达到 468.7 亿美元，2025 年至 2032 年的复合年增长率为 4.2%。
| 报告内容 | 报告详情 | ||
|---|---|---|---|
| 基准年： | 2024 | 2025年市场规模： | 351.4亿美元 |
| 历史数据时期： | 2020-2024 | 预测期： | 2025-2032 |
| 预测期间（2025-2032年）： | 4.20% | 2032 年的预测值： | 468.7亿美元 |
全球药物再利用市场代表了一种创新的药物开发方法，专注于为已已通过核准的药物寻找新的治疗用途，从而显着缩短传统药物开发的时间和相关成本。
药物再利用（也称为药物重定位或治疗用途再利用）利用现有药物已确立的安全性和药理特性，来满足不同疾病领域尚未满足的医疗需求。近年来，这项创新策略发展迅速，尤其是在Sildenafil（最初用于治疗高血压，后来用于治疗勃起功能障碍）等成功案例之后，以及近期现有抗病毒药物迅速应用于新冠肺炎治疗之后。
该市场由先进的计算方法、人工智慧和复杂的筛检技术所驱动，涵盖肿瘤学、神经系统疾病、感染疾病、心血管疾病和罕见疾病等各种治疗领域。
慢性病的增加、医疗保健成本的不断攀升以及对快速药物开发解决方案的迫切需求，使得药物再利用成为现代製药策略的关键要素，为全球製药公司在降低开发风险、缩短监管流程和提高投资回报率方面带来了显着的益处。
市场动态
全球药物再利用市场主要受以下几个强大因素驱动，这些因素正在改变製药业的结构并加速市场成长：传统药物开发成本不断增加且开发週期长（超过 26 亿美元，10-15 年），这促使製药公司采用药物再利用策略，该策略可将开发成本降低高达 60%，并将开发时间缩短至 3-12 年。
慢性病的增加、全球人口老化以及治疗罕见疾病和新出现的健康威胁的迫切性，都对创新治疗方案产生了巨大的需求。
然而，该市场面临许多限制因素，例如复杂的智慧财产权问题、药物再利用核准管道的监管不确定性，以及学名药生产商缺乏投资药物再利用研发的经济奖励。此外，各地区缺乏统一的法规结构、新适应症使用可能带来的安全隐患，以及来自生物相似药和学名药的竞争，都对市场成长构成重大挑战。
儘管存在这些限制，但市场仍存在巨大的机会，这得益于政府对再利用倡议的支持和资金不断增加、製药公司与学术机构之间的伙伴关係日益密切、精准医疗和个性化治疗方法的应用不断扩展，以及人工智能驱动的药物发现平台的日益普及。
本次调查的主要特点
- 本报告对全球药物再利用市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和復合年增长率（%）。
- 它还重点介绍了各个细分市场的潜在商机，并解释了该市场具有吸引力的投资提案矩阵。
- 该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、市场趋势、区域展望以及主要参与企业。
- 该报告根据以下参数对全球药物再利用市场的主要参与企业进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
- 本报告的研究结果将使负责人和企业经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 这份全球药物再利用市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
- 透过分析全球药物再利用市场的各种策略矩阵，可以促进相关人员的决策。
目录
第一章 研究目标与前提条件
- 调查目的
- 先决条件
- 简称
第二章 市场范围
- 报告概述
- 市场定义和范围
- 执行摘要
第三章：市场动态、监理及趋势分析
- 市场动态
- 司机
- 抑制因素
- 机会
- 影响分析
- 法规环境
- 产品上市及核准
- PEST分析
- 波特分析
- 併购趋势
- 产业趋势
4. 2020-2032年全球药物再利用市场（依方法划分）
- 以疾病为中心
- 以目标为中心
- 以药物为中心
5. 2020-2032年全球药物再利用市场（依药物类型划分）
- 低分子化合物
- 生技药品
6. 2020-2032年全球药物再利用市场（依治疗领域划分）
- 肿瘤学
- 神经病学和中枢神经系统疾病
- 感染疾病
- 心血管疾病
- 代谢性疾病
- 其他的
7. 2020-2032年全球药物再利用市场（依给药途径划分）
- 口服
- 静脉注射
- 其他频道
8. 2020-2032年全球药物再利用市场（依最终用户划分）
- 製药和生物技术公司
- 受託研究机构（CRO）
- 医院和诊所
- 其他的
9. 2020-2032年全球药物再利用市场（按地区划分）
- 北美洲
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲国家
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 亚太其他地区
- 中东
- GCC
- 以色列
- 其他中东国家
- 非洲
- 南非
- 北非
- 中非
第十章 竞争格局
- Pfizer Inc.
- Novartis AG
- Bristol Myers Squibb Company
- Johnson and Johnson
- AstraZeneca PLC
- Eli Lilly and Company
- Sanofi SA
- GlaxoSmithKline PLC
- Amgen Inc.
- Recursion Pharmaceuticals Inc.
- Melior Discovery Inc.
- Vertex Pharmaceuticals Incorporated
- Ginkgo Bioworks, Inc.
- Paradigm Biopharmaceuticals Ltd
- Teva Pharmaceutical Industries Ltd.
第十一章 分析师建议
- 机会
- 一致的机会地图
第十二章 参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Drug Repurposing Market is estimated to be valued at USD 35.14 Bn in 2025 and is expected to reach USD 46.87 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.2% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 35.14 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 4.20% | 2032 Value Projection: | USD 46.87 Bn |
The global drug repurposing market represents a revolutionary approach in pharmaceutical development that focuses on identifying new therapeutic applications for existing approved drugs, significantly reducing the traditional drug development timeline and associated costs.
Drug repurposing, also known as drug repositioning or therapeutic switching, leverages the established safety profiles and pharmacological properties of existing medications to address unmet medical needs across various disease areas. This innovative strategy has gained substantial momentum in recent years, particularly following successful repurposing examples such as sildenafil (originally for hypertension, later for erectile dysfunction), and more recently, the rapid deployment of existing antivirals for COVID-19 treatment.
The market encompasses various therapeutic areas including oncology, neurological disorders, infectious diseases, cardiovascular conditions, and rare diseases, driven by advanced computational methods, artificial intelligence, and sophisticated screening technologies.
The growing prevalence of chronic diseases, increasing healthcare costs, and the urgent need for faster drug development solutions have positioned drug repurposing as a critical component of modern pharmaceutical strategies, offering significant advantages in terms of reduced development risks, shortened regulatory pathways, and improved return on investment for pharmaceutical companies worldwide.
Market Dynamics
The global drug repurposing market is primarily driven by several compelling factors that are reshaping the pharmaceutical landscape and accelerating market growth. The escalating costs and extended timelines associated with traditional drug development, which can exceed $2.6 billion and span 10-15 years, are compelling pharmaceutical companies to adopt drug repurposing strategies that can reduce development costs by up to 60% and shorten timelines to 3-12 years.
The increasing prevalence of chronic diseases, aging global population, and the urgent need for treatments for rare diseases and emerging health threats are creating substantial demand for innovative therapeutic solutions.
However, the market faces significant restraints including complex intellectual property challenges, regulatory uncertainties regarding approval pathways for repurposed drugs, and limited financial incentives for generic drug manufacturers to invest in repurposing research. Additionally, the lack of standardized regulatory frameworks across different regions, potential safety concerns when drugs are used for new indications, and competition from biosimilars and generic alternatives pose considerable challenges to market growth.
Despite these constraints, the market presents substantial opportunities driven by increasing government support and funding for repurposing initiatives, growing partnerships between pharmaceutical companies and academic institutions, expanding applications in precision medicine and personalized therapy approaches, and the rising adoption of AI-driven drug discovery platforms.
Key Features of the Study
- This report provides in-depth analysis of the global drug repurposing market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global drug repurposing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as part of this study include Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, AstraZeneca PLC, Eli Lilly and Company, Sanofi S.A., GlaxoSmithKline PLC, Amgen Inc., Recursion Pharmaceuticals Inc., Melior Discovery Inc., Vertex Pharmaceuticals Incorporated, Ginkgo Bioworks Inc., Paradigm Biopharmaceuticals Ltd, and Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global drug repurposing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global drug repurposing market
Market Segmentation
- Approach Insights (Revenue, USD Bn, 2020 - 2032)
- Disease centric
- Target centric
- Drug centric
- Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Small molecules
- Biologics
- Therapeutic Area Insights (Revenue, USD Bn, 2020 - 2032)
- Oncology
- Neurology and CNS disorders
- Infectious diseases
- Cardiovascular diseases
- Metabolic disorders
- Other therapeutic areas
- Route Of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Intravenous (IV)
- Other routes
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Pharmaceutical and biotechnology companies
- Contract research organizations (CROs)
- Hospitals and Clinics
- Others
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Novartis AG
- Bristol Myers Squibb Company
- Johnson and Johnson
- AstraZeneca PLC
- Eli Lilly and Company
- Sanofi S.A.
- GlaxoSmithKline PLC
- Amgen Inc.
- Recursion Pharmaceuticals Inc.
- Melior Discovery Inc.
- Vertex Pharmaceuticals Incorporated
- Ginkgo Bioworks, Inc.
- Paradigm Biopharmaceuticals Ltd
- Teva Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Drug Repurposing Market, By Approach
- Global Drug Repurposing Market, By Drug Type
- Global Drug Repurposing Market, By Therapeutic Area
- Global Drug Repurposing Market, By Route of Administration
- Global Drug Repurposing Market, By End User
- Global Drug Repurposing Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Drug Repurposing Market, By Approach, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Disease centric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Target centric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Drug centric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Drug Repurposing Market, By Drug Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Small molecules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Drug Repurposing Market, By Therapeutic Area, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Neurology and CNS disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Infectious diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cardiovascular diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Metabolic disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other therapeutic areas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Drug Repurposing Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intravenous (IV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other routes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Drug Repurposing Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pharmaceutical and biotechnology companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Contract research organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Drug Repurposing Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Approach, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Approach, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Approach, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Approach, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Approach, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Approach, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson and Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Recursion Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Melior Discovery Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Vertex Pharmaceuticals Incorporated
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ginkgo Bioworks, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Paradigm Biopharmaceuticals Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
